Pathway / Off-pathway / systemic markers

Sodium-glucose co-transporter 2

SLC5A2gene

Renal electrolyte handling with indirect MI risk via glycemic control, not atherothrombotic pathway.

Pathway placement

Cascade stepOff-pathway / systemic markers

Confidencehigh

RationaleRenal glucose reabsorption; glycemic/systemic risk factor; off-pathway.

Druggability

DruggableYes

Known drugs / candidates17

Small-molecule tractableYes

Antibody tractableYes

EnsemblENSG00000140675

Type I vs Type II discrimination

ScoresIndeterminate

R — rupture / Type-I

—

C — confounder / Type-II

A — assay feasibility

E — evidence strength

T1DI (composite)

Specificity differential (R−C)+15

Confounder panel (Type-II drivers)

1sepsis / systemic inflammationn/a

2anemia / acute blood lossn/a

3hypovolemia / dehydrationmag 0

4tachyarrhythmian/a

5hypoxemia / respiratory failuren/a

6hypertensive emergencyn/a

7high-demand / peri-operative stressn/a

Coverage: 1/7 confounders with evidence

Tier: deep-scored (abstract-extracted) · 1 supporting references. See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Whole blood — gene is not a circulating analyte; measure protein product or genotype

Collection tube

K2-EDTA whole blood (lavender-top)

Method / principle

SNP genotyping / sequencing; or immunoassay of encoded protein

Reagent / substrate

Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein

Platform

qPCR / NGS / array

Turnaround · availability

Send-out · Genotyping widely available; protein assay variable

Human genetic evidence

0.352

Open Targets association (acute_MI)

Literature evidence(0)

No direct literature mentions harvested; included via genetic/target evidence.